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Abstract
Biosimilars are biological products similar to, but not the same as, the innovator products. Both the European Medicines Agency
and the Food and Drug Administration have released detailed guidance on the development of biosimilars. This guidance requires
the pivotal phase 3 clinical study to have an equivalence design, which means that the study objective is to demonstrate that one
treatment is neither “worse than” nor “better than” the other by some “clinically unimportant” amount. The most critical and
controversial step in designing such a study is the choice of equivalence margin, as this determines the conclusion of the study. In
this paper, we outline the methodology for determining an equivalence margin and, through case studies on biosimilar trastu-
zumab (HERCEPTIN ) and biosimilar bevacizumab (AVASTIN), explain the challenges of applying this in practice and why the
synthesis method should be given greater consideration by regulatory authorities and biosimilar developers.
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A biosimilar program usually consists of a phase 1 study to
demonstrate pharmacokinetic similarity (area under the
curve [AUC] and maximum observed concentration
[Cmax]) and a phase 3 study to demonstrate comparable
efficacy, safety, and immunogenicity. For the latter, the
European Medicines Agency (EMA) and the Food and Drug
Administration (FDA) both stipulate that an equivalence
design is required.1,2
In an equivalence design, the goal is to show that two treat-
ments are therapeutically equivalent, that is, that the difference
between the treatments lies within a predefined equivalence
margin.3 Two treatments would be considered equivalent if the
upper and the lower bounds of the confidence interval of the
observed difference does not cross the prespecified margin.4
Normally 95% confidence limits are used, although in bioequi-
valence trials it is the norm to use 90% limits.4
Two of the most commonly used methods to selecting the
margin are the fixed margin (or 95-95) approach and the synth-
esis method (also known as the putative placebo method).4-7
Both methods are outlined in the draft FDA guideline on non-
inferiority, which was published in March 2010.7
Finally, it should be mentioned for completeness that Baye-
sian approaches can yield reduced sample sizes, but these will
not be specifically addressed in this paper.8
Fixed Margin
The hypotheses for the fixed margin approach can be expressed
as follows:
H0: mT  mC  –D or mT  mC  þD versus H1: –D < mT
 mC < þD,
where –D (0) and þD (0) are the prespecified fixed
margins.9
Equivalence is concluded when each one-sided null
hypothesis is rejected or, equivalently, if the 1 – 2a (eg,
90%) two-sided confidence interval of the treatment differ-
ence, mT  mC, lies entirely inside [+D].
According to the FDA guidance, the first step in the fixed-
margin method is to define the largest acceptable margin (M1)
and the clinical margin (M2), which are key parameters for the
sample size calculation. M1 is the effect of the active control,
which is an assumed value based on the analysis of the effect of
the active control seen in past controlled studies. M2 reflects
the clinical judgment about how much of M1 should be pre-
served by ruling out a loss of M2.
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The determination of M2 is based on clinical judgment and
is usually calculated by taking a percentage or fraction of M1.
The clinical judgment in determining M2 may take into
account the actual disease incidence or prevalence and its
impact on the practicality of sample sizes that would have
to be accrued for a study. There can be flexibility in the M2
margin, for example, when the difference between the active
comparator response rate and the spontaneous response rate is
large or the primary endpoint does not involve an irreversible
outcome such as death (in general, the M2 margin will be
more stringent when treatment failure results in an irreversi-
ble outcome).
Synthesis
The hypotheses for the synthesis method can be expressed as
follows:
H0: mT mP lL (mC mP) or mT mP lU (mC mP)
versus
H1: lU  (mC  mP) > mT  mP > lL (mC  mP)
where lL and lU are the pre-specified preservation and infla-
tion factors (0  lL  1 and lU  1), respectively.9 Equiva-
lence is concluded if the test treatment preserves at least 100 
lL% and does not exceed 100  lU% of the treatment effect
observed with the active control in previous studies.
The synthesis method is designed to directly address the
question of whether the test product would have been superior
to a placebo had a placebo been in the study, and also to address
the related question of what fraction of the active comparator’s
effect is maintained by the test product.4,7 Use is made of the
variability from the proposed trial and the historical trials and
one confidence interval is constructed for testing the equiva-
lence hypothesis that the treatment preserves a fixed fraction of
the control effect, without actually specifying the size of the
control effect (M1 in the fixed-margin approach) or a specific
fixed equivalence margin based on the control effect. Clinical
judgment is used to prespecify an acceptable fraction of the
control therapy’s effect (M2 in the fixed-margin approach) that
should be retained by the test drug, regardless of the magnitude
of the control effect.
The EMA View
The EMA published a guidance document on the choice of the
Non inferiority (NI) margin in July 2005.10 The guideline,
which applies equally to the choice of equivalence margin,
does not specify a method for choosing the margin. The choice
of margin should be “based upon a combination of statistical
reasoning and clinical judgement” and should provide evidence
that the test product would have been shown to be efficacious if
a placebo controlled trial had been performed.
The EMA argues that to adequately choose delta, an
informed decision must be taken, supported by evidence of
what is considered an unimportant difference in the particular
disease area. If there are already many treatments being used
interchangeably for the disease under consideration a possible
approach might be to consider the information available from
all of them. A delta may then be constructed based on the
information known about the relative efficacy of these prod-
ucts. If there is only one product on the market then a “survey
of practitioners on the range of differences that they consider to
be unimportant” may be the best way to choose delta.
Choosing the Margin
All methods depend to some extent on historical data and clin-
ical judgment and are inevitably subjective. Nonetheless, in
order to ensure that decisions are as informed as possible, it
is essential to gather all relevant information through a com-
prehensive literature search and/or evaluation of internal data-
bases. The overall estimate of the treatment effect and
population variability observed in historical studies with the
active control should be determined quantitatively, ideally by
meta-analysis.
We will now describe how an equivalence margin for bio-
similar trastuzumab (HERCEPTIN) and biosimilar bevacizu-
mab (AVASTIN) can be constructed using these techniques.
Trastuzumab
For the purpose of establishing the therapeutic equivalence of
an oncology biosimilar, a randomized, double-blind, parallel-
group, multicenter phase III trial comparing the efficacy,
safety, immunogenicity, and pharmacokinetics in combination
with backbone chemotherapy is usually performed. Trastuzu-
mab is approved for several indications in Europe and the USA,
including metastatic breast cancer (MBC), early breast cancer,
and metastatic gastric cancer. The choice of target patient pop-
ulation is complex and involves balancing regulatory and sci-
entific considerations with operational demands.11 We will
consider a study in patients with HER2-positive MBC.
The objective of a biosimilar study is not to demonstrate
patient benefit per se, as that has already been demonstrated
with the reference product, rather that the biosimilar medicine
exhibits similar efficacy (and safety) to the reference medicinal
product (the originator product). For this reason, the primary
endpoint for biosimilar oncology studies would not be the tra-
ditional time-to-event endpoints such as overall survival (OS)
or progression-free survival (PFS), but measures of activity,
such as Overall Response Rate (ORR, proportion of patients
in whom a Complete Response (CR) or Partial Response (PR)
was observed). PFS and OS should also be included, but as part
of the secondary endpoints.
So after having selected our target population and primary
endpoint we can now focus on constructing the equivalence
margin. The first step in establishing the equivalence margin
is to identify all relevant publication pertaining to the pro-
posed study. Table 1 outlines the relevant studies that were
identified from
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1. Herceptin: European Public Assessment Report—
Scientific Discussion12
2. Herceptin: European Public AssessmentReport—Product
Information13
3. FDA label for trastuzumab (Revised 02/2010)14
4. FDA Medical Statistical Review for trastuzumab15
5. Literature search for published randomized studies of
trastuzumab for use in breast cancer using the key
words: trastuzumab and breast cancer.
Two studies of trastuzumab with taxane in the treatment of
patients with HER2-positive MBC were identified for the pur-
poses of determining the effect size.16,17 Table 1 and Figure 1
show the results of a meta-analysis of the proposed primary end
point (ORR) from these studies. The combined effect size for
the risk difference (28.0% [17.9%, 38.1%]; P ¼ .502) and
relative risk or risk ratio (1.9 [1.452, 2.512]; P ¼ .095), which
were calculated using the inverse variance-weighted method,
was homogeneous across studies. The combined effect size or
the lower bound of the 95% confidence interval of the risk
difference (17.9%) or the relative risk (1.452) can be viewed
as the largest acceptable margin (M1). From a clinical perspec-
tive, it is not uncommon to use 50% of M1 as the clinical
margin (M2).4,18
It is noteworthy that the EMA and FDA approach to the use
of risk difference and relative risk can vary, as evidenced by the
recent approval of ABP 501, where the EMA stated that “It is
considered acceptable to present the results as [risk ratio] RR,”
whereas the FDA stated that “a margin based on the absolute
difference scale [should] be used, as it is considered more
important than other metrics, such as risk ratio, from a clinical
perspective for an evaluation of benefit-risk.”19,20 The use of
Figure 1. Meta-analysis of objective response rate (ORR) for trastuzumab.
Table 1. Meta-analysis of Objective Response Rate (ORR) for Trastuzumab.
Referencea/
Study number/name Taxane þ Trastuzumab Taxane Only
Effect size
Risk Difference Risk Ratio
11, 15 / M77001 (with Docetaxel) n ¼ 92 n ¼ 94
56 (60.9%) 34 (36.2%) 24.7% 1.67
11, 16 / H0648gb (with Paclitaxel) n ¼ 68 n ¼ 77
33 (49%) 13 (17%) 31.7% 2.87
Combined effect sizec (95% CI) 28.0%d (17.9%, 38.1%) 1.9e (1.452, 2.512)
aAs per Reference list. Data taken from the “Herceptin: European Public Assessment Report—Scientific Discussion.”12
bSubgroup of IHC3þ patients.
cUsing the inverse variance-weighed method.
dP value of homogeneity test ¼ .502.
eP value of homogeneity test ¼ .095.
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absolute difference or risk ratio also seems to depend on the
study population. For example, we have seen the FDA request
risk difference and relative risk for different indications for the
same biosimilar compound.
Table 2 summarizes the sample sizes for each value of M2
for the fixed-margin and synthesis methods assuming a primary
endpoint of Risk Difference. The synthesis margin was derived
using “preservation” of effect method as discussed by Carrol
and extended to biosimilar trials by Yining and Bin.9,21 Table 3
presents analogous information assuming a primary endpoint
of Relative Risk. There is as yet no published validated meth-
odology for applying synthesis to equivalence studies with
Relative Risk, but given that synthesis can be applied to both
parameters in the non-inferiority setting, there is no reason why
this cannot be done.7 As can be seen, the method for determin-
ing the margin can significantly impact the number of patients
to be recruited to demonstrate biosimilarity. The sample sizes
required to establish equivalence range from 167 (50% of the
relative risk) to 640 (fixed-margin using lower bound of the
confidence interval) patients per group.
A like-for-like comparison of the synthesis and fixed-
margin methods shows that the former is statistically more
efficient (smaller sample size), as the standard error will always
be smaller than that of the fixed-margin method.4 There is as
yet no published methodology for using the synthesis method
in equivalence trials with risk ratio.
Bevacizumab
The above issues are not that dissimilar for other biosimilar
compounds. Tables 4 and 5 show M2 and sample sizes for
bevacizumab adopting the same strategy as above for trastuzu-
mab with a primary endpoint of ORR, assuming a primary end
point of Risk Difference and Relative Risk. The effect size for
the risk difference and relative risk from a meta-analysis of
studies in patients with non–small cell lung cancer (NSCLC)
was 17.3% [13.7%, 20.9%] and 1.849 [1.615, 2.116], respec-
tively.22-24 The P values for homogeneity test were 0.1539 and
0.224, respectively. For bevacizumab, the range of sample
sizes required to demonstrate therapeutic equivalence varies
from 367 to 1012 patients per group with the synthesis method,
again more statistically efficient than the fixed-margin
Table 4. M2 and Sample Sizes for Bevacizumab, Objective Response
Rate, Risk Difference.
Methodology M2a Sample Size per Arm
Fixed-margin: 50%
effect size
+9% 612b
Fixed-margin: 50%
lower bound
+7% 1012b
Synthesis H1: pe – pc > –9%
and pe – pc < 9%
516c
aRisk difference from meta-analysis: 17.3% (13.7%, 20.9%); P value of
homogeneity test ¼ 0.1539.22-24
bEquivalence test for 2 proportions using differences, PASS 13 (80% power,
actual difference ¼ 0.0, alpha ¼ 0.025, reference group proportion ¼ 0.381).
cTOST (Two One-Sided Test) at the .05 level, 80% power, reference group
proportion ¼ 0.381.
Table 2. M2 and Sample Sizes for Trastuzumab, Objective Response
Rate, and Risk Difference.
Methodology M2
Sample Size
per Arm
Fixed-margin: 50% effect size +14% 265a
Fixed-margin: 50% lower bound +9% 640a
Synthesis H1: pe – pc > –14%
and pe – pc <14%
203b
aEquivalence test for two proportions using differences, PASS 13 (80% power,
actual difference ¼ 0.0, alpha ¼ 0.025, reference group proportion ¼ 0.559).
bTOST (Two One-Sided Test) at the .05 level, 80% power, reference group
proportion ¼ 0.559.
Table 3. M2 and Sample Sizes for Trastuzumab, Objective Response
Rate, Relative Risk.
Methodology M2a Sample Size per Armb
Fixed-margin: 50% effect size 0.725, 1.378 167
Fixed-margin: 50% lower bound 0.830, 1.205 483
aEquivalence margin calculated as exp(ln[1/D])  (1 – 0.5).
bEquivalence test for two proportions using ratios, PASS 13 (80% power, actual
ratio ¼1.0, alpha ¼ 0.025, reference group proportion ¼ 0.559).
Table 5. M2 and Sample Sizes for Bevacizumab, Objective Response
Rate, Relative Risk.
Methodology M2a,b Sample Size per armc
Fixed-margin: 50% effect size 0.735, 1.360 367
Fixed-margin: 50% lower bound 0.787, 1.271 601
aRelative risk from meta-analysis: 1.849 (1.615, 2.116); P value of homogeneity
test ¼ 0.224. Meta-analysis of previous studies with bevacizumab in patients
with NSCLC.22-24
bEquivalence margin calculated as exp (ln[1/D])  (1 – 0.5).
cEquivalence test for two proportions using ratios, PASS 13 (80% power, actual
ratio ¼1.0, alpha ¼ 0.025, reference group proportion ¼ 0.381).
Table 6. M2 and Sample Sizes for Bevacizumab, Objective Response
Rate, Risk Difference.
Methodology M2a
Sample Size
per Arm
Fixed-margin: 50% effect size +10% 510b
Fixed-margin: 50% lower bound +8% 800b
Synthesis H1: pe – pc > –10%
and pe – pc < 10%
423c
aRisk difference from meta-analysis: 20.6% (15.3%, 26.0%); P value of
homogeneity test ¼ 0.347. Meta-analysis of previous studies with bevacizumab
in patients with NSCLC.22,23,25
bEquivalence test for 2 proportions using differences, PASS 13 (80% power,
actual difference ¼ 0.0, alpha ¼ 0.025, reference group proportion ¼ 0.402).
cTOST (Two One-Sided Test) at the .05 level, 80% power, reference group
proportion ¼ 0.381.
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approach on a like-for-like comparison. Tables 6 and 7 show
that the effect size for the risk difference and relative risk are
highly dependent on the studies included in the meta-analysis.
Conclusion
The choice of acceptance margin for non-inferiority and
equivalence studies is controversial.4,18 As can be seen from
the biosimilar trastuzumab (Herceptin) and biosimilar bevaci-
zumab (Avastin) case studies, the resulting sample sizes differ
significantly depending on the choice of margin and metho-
dology used. Furthermore, the effect size on which the margin
is decided can differ quite markedly depending on the studies
included in the meta-analysis and the percentage of the treat-
ment effect that is retained. In the recent approval of biosimilar
Humira (adalimumab), the FDA questioned the studies
included in the meta-analysis performed by the sponsor
company.26
The synthesis method is more statistically efficient than the
fixed-margin approach but, in our experience, is rarely if ever
used in biosimilar studies. The reasons often given are the
absence of a fixed margin, which renders the outcome of the
study difficult to interpret, and the sensitivity of the method to
the constancy assumption (ie, that the treatment effect observed
in the equivalence study is consistent with that seen in histor-
ical trials). However, the margin is by its very nature highly
subjective, and the outcome of such a study should not be the
sole arbiter of whether a biosimilar product is equivalent (or
not) to the originator. As stated in the regulatory guidance on
biosimilars, the decision on biosimilarity should be based on
the totality of the data and not on the outcome of any one
study.1,2 Furthermore, both the fixed-margin and the synthesis
methods require the constancy assumption to be fulfilled.4
We argue that demonstrating that the biosimilar product
retains a predefined fraction of the treatment effect should
suffice with the proviso that comparability to the reference
product in terms of physicochemical, in vitro functional char-
acteristics, and nonclinical and clinical pharmacokinetic and
pharmacodynamic profiles have all been demonstrated in
well-designed studies.
Large comparative clinical trials defeat the object of the
abbreviated development pathway for biosimilars adopted by
regulatory authorities. Adoption of approaches such as the synth-
esis method for choosing the margin could potentially result in
smaller studies and facilitate patient access to alternative ther-
apy. We would therefore encourage biosimilar developers to
discuss the use of this method with regulatory authorities during
the planning stages of the pivotal phase 3 trial.
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